CAR T cells targeting CD20 and CD19 for B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on cancer cells. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a B-cell cancer like lymphoma or leukemia that has returned or not responded to treatment.
- You have tried at least two prior treatments, including certain targeted therapies for some cancer types.
- Your heart, liver, kidneys, and lungs are working well enough.
- You have not had certain other cancer treatments within a specific time before starting this trial.
- You are willing to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has come back or did not respond to previous treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.